Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
remibrutinib - BTK inhibitor
Company overview
Financial review
Conclusions
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Cardiovascular, Renal
and Metabolic
> Immunology
Neuroscience
Oncology
Other
Global Health
Abbreviations
References
NCT05976243 (CLOU064M12301)
Chronic inducible urticaria
Phase 3
Indication
Phase
Patients
348
Primary
Outcome
Measures
Arms
Intervention
Target Patients
Readout
Milestone(s)
1. Proportion of participants with complete response in Total Fric Score;
symptomatic dermographism [ Time Frame: Week 12]
2. Proportion of participants with complete response in critical temperature
threshold; cold urticaria [ Time Frame: Week 12]
3. Proportion of participants with itch numerical rating scale =0; cholinergic
urticaria [ Time Frame: Week 12]
All arms oral, twice daily:
Arm 1 Experimental Remibrutinib, symptomatic dermographism group
Arm 2 Placebo symptomatic dermographism group
Arm 3 Experimental Remibrutinib, cold urticaria group
Arm 4 Placebo cold urticaria group
Arm 5 Experimental Remibrutinib, cholinergic urticaria group
Arm 6 Placebo cholinergic urticaria group
Adults suffering from CINDU inadequately controlled by H1-antihistamines
2026
Publication
TBD
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
64View entire presentation